StemCells, Inc. to Announce Interim Data on Spinal Cord Injury Trial at the 2012 Annual Scientific Meeting of the International Spinal Cord Society Date: August 30, 2012 Client: StemCells, Inc. Summary: NEWARK, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Armin Curt, MD, Professor and Chairman of the Spinal Cord Injury Center at Balgrist University Hospital, University of Zurich, and principal investigator for the Company's Phase I/II clinical trial in chronic spinal cord injury, will make an oral presentation on the progress of the trial on Monday, September 3 at the 51st Annual Scientific Meeting of the International Spinal Cord Society (ISCOS), which is being held in London, England, on September 3-5, 2012.
		Debiopharm Group Presents the 'Debiopharm Group Life Sciences Award 2012'and Two 'Junior Debiopharm Group Life Sciences Awards 2012' During the Annual EPFL SV- Life Science Symposium Date: August 30, 2012 Client: Debiopharm Group Summary: Lausanne, Switzerland - August 30, 2012 - Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today presents the 'Debiopharm Grou(TM) Life Sciences Award 2012' in collaboration with EPFL (Ecole polytechnique federale de Lausanne) to Professor Daniel D. Pinschewer for his outstanding research in the field of Infectious Diseases and Immunology. Furthermore, Doctors Daan Noordermeer and Kelly Tan each receive a 'Junior Debiopharm Grou(TM) Life Sciences Award 2012' for their research in the field of Cellular and Molecular Biology. Organised by the Global Health Institute (GHI), the ceremony is taking place at the EPFL during the Annual EPFL SV- Life Science Symposium 2012 on the theme 'Global Health meets Infection Biology'.
		Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference Date: August 29, 2012 Client: Cempra, Inc. Summary: CHAPEL HILL, N.C., Aug. 29, 2012 - Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the 2012 Stifel Nicolaus Healthcare Conference at 10:20 a.m. EDT, Sept. 5, at the Four Seasons Hotel in Boston, and at the NewsMakers in the Biotech Industry conference at 9:30 a.m. EDT, Sept. 7, at the Millennium Broadway Hotel & Conference Center in New York. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and uncomplicated gonococcal infection and TAKST(TM) for the oral treatment of prosthetic joint infections from gram positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA).
		Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference Date: August 29, 2012 Client: PUMA Biotechnology, Inc. Summary: LOS ANGELES, Calif., Aug. 29, 2012 - Puma Biotechnology, Inc. (OTCBB: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 11:30 a.m. EDT on Wednesday, September 5, at the Stifel Nicolaus 2012 Healthcare Conference in Boston.
		Amarin Announces Additional Publication of MARINE Phase 3 Clinical Trial Results in the Journal of Clinical Lipidology Date: August 29, 2012 Client: Amarin Corp. Summary: BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 28, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE Phase 3 clinical trial are now available electronically through the Journal of Clinical Lipidology and are expected to be published in a future print issue of the journal before the end of 2012.
		Endocyte, Inc. to Present at Upcoming Health Care and Investor Conferences Date: August 28, 2012 Client: Endocyte, Inc. Summary: WEST LAFAYETTE, Ind., Aug 28, 2012 (GlobeNewswire via COMTEX) -- Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that their company's management team will present at the following upcoming conferences...
		Aragon Pharmaceuticals Announces Appointment of Faheem Hasnain as Independent Director Date: August 28, 2012 Client: Aragon Pharmaceuticals Summary: SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- Aragon Pharmaceuticals today announced the appointment of Faheem Hasnain as an independent director of the Company's board of directors.
		Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease Date: August 28, 2012 Client: Resverlogix Corp. Summary: MUNICH and CALGARY, Alberta, August 28, 2012 - Resverlogix Corp. (TSX: RVX) today announced that the BET protein inhibitor RVX-208 significantly increased HDL-C (p=0.001), the primary endpoint of the SUSTAIN trial, a phase 2b clinical study. SUSTAIN also successfully met secondary endpoints, showed increases in levels of Apo-AI (p=0.002) and large HDL particles (p=0.02), both believed to be important factors in enhancing reverse cholesterol transport activity. The SUSTAIN trial also showed that increases in alanine aminotransferase (ALT) reported in previous trials were infrequent and transient with no new increases observed beyond week 12 of the 24-week trial.
		Resverlogix Secures $25 Million, Five-Year Term Loan Date: August 27, 2012 Client: Resverlogix Corp. Summary: August 27, 2012 (Calgary, AB) - Resverlogix Corp. (TSX:RVX) today announced that it has entered into a $25 million Loan Agreement with Citibank, N.A. ("Citibank"). Resverlogix received the $25 million upon closing of the loan. The loan is repayable upon maturity on August 24, 2017 and may be repaid in whole or in part after August 23, 2013 without penalty. Interest on the loan is payable annually in arrears at 4.5% per annum for the first year of the loan and thereafter at a rate equal to Canadian one-year LIBOR swap rate plus 3.14%, to be reset annually. The loan is secured by an irrevocable $25 million Standby Letter of Credit (the "Letter of Credit") arranged by Eastern Capital Limited ("Eastern") which will be maintained until maturity of the loan.
		ZIOPHARM Oncology to Present at BioCentury's NewsMakers in the Biotech Industry Conference Date: August 27, 2012 Client: Ziopharm Oncology, Inc. Summary: NEW YORK, Aug. 27, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jason A. Amello, Executive Vice President and Chief Financial Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012 at 3:00 p.m. ET at The Millennium Broadway Hotel & Conference Center in New York City.
		Debiopharm Announces First Patient Enrolled in Phase III Study for the rare disease Central Precocious Puberty Date: August 27, 2012 Client: Debiopharm Group Summary: Lausanne, Switzerland - August 27, 2012 - Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.
		Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohn's Disease Date: August 27, 2012 Client: Alder Biopharmaceuticals, Inc. Summary: BOTHELL, Wash., Aug. 27, 2012 -- /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 Z*(IL-6), in Crohn's disease.
		Elena Breezed Through Brain Surgery at Yale Children's Hospital and Now She's Giving Back (video) Date: August 17, 2012 Client: IMRIS Summary: NEW HAVEN, CT - Looking at Elena Soviero, you wouldn't know that almost a year and a half ago, she went through a frightening brain surgery.
		Puma Biotechnology Reports Second Quarter 2012 Financial Results Date: August 17, 2012 Client: Puma Biotechnology, Inc. Summary: LOS ANGELES, Calif., Aug. 14, 2012 Puma Biotechnology, Inc. (OTCBB: PBYI), a development stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2012.
		World First - Islet Transplant Into Man Using Sernova's Cell Pouch(TM) For Treatment Of Diabetes Date: August 17, 2012 Client: Sernova Corp. Summary: LONDON, ONTARIO and EDMONTON, ALBERTA (Marketwire -- August 16, 2012) -- Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) and the University of Alberta today announced the treatment of the first patient with insulin-producing islets transplanted into Sernova's Cell Pouch(TM) in a Phase I/II clinical study to treat Type-1 diabetes led by Dr. James Shapiro, Professor of Surgery and Medicine, University of Alberta and Director, Clinical Islet Transplant Program. Sernova will host a conference call at 9 a.m. EDT, today, Aug. 16, 2012, to discuss the company's clinical and business developments.
		Sernova Breaks New Ground in Islet Cell Transplantation Date: August 17, 2012 Client: Sernova Corp. Summary: Sernova Corp., of London, Ontario, is taking islet cell transplantation to the next level by combining transplanted insulin-producing islet cells with its Cell Pouch device in a Phase I/II trial in patients with Type I diabetes. (See BioWorld Today, Aug. 17, 2012.)
		Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor Debio 0932 Date: August 15, 2012 Client: Debiopharm Group Summary: Lausanne, Switzerland and Lexington, Mass., August 15, 2012 - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group(TM) (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in its HALO Phase I/II clinical trial of orally-administered Heat Shock Protein 90 (HSP90) inhibitor Debio 0932 in combination with chemotherapy regimens in patients with advanced stages of non-small cell lung cancer (NSCLC).
		CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells Date: August 14, 2012 Client: Cellular Dynamics International Summary: MADISON, WIS., August 14, 2012 - CeeTox and Cellular Dynamics International (CDI) today announced the introduction of a new, highly predictive cardiac safety screening service that utilizes human induced pluripotent stem (iPS) cell-derived cardiomyocytes. The Cardiac Arrhythmia Assessment Scree(TM) (CAAS) combines CeeTox's expertise with in vitro toxicity screening and CDI's iCell(R) Cardiomyocytes to provide a comprehensive profile of drug-induced cardiac toxicity early in the drug development cycle.
		Endocyte Announces Presentations at the 244th American Chemical Society Meeting & Exposition Date: August 14, 2012 Client: Endocyte, Inc. Summary: WEST LAFAYETTE, Ind., Aug 14, 2012 (GlobeNewswire via COMTEX) -- Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that three posters will be presented by Endocyte scientists at the 244th American Chemical Society (ACS) Meeting & Exposition to be held in Philadelphia, Aug. 19-23, 2012.
		Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments Date: August 9, 2012 Client: Arena Pharmaceuticals, Inc. Summary: SAN DIEGO, Aug. 9, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the second quarter ended June 30, 2012, and reviewed recent developments.
		Curetis AG and Cempra, Inc. Collaborate on the Detection of Community-Acquired Bacterial Pneumonia Date: August 9, 2012 Client: Cempra, Inc. Summary: Holzgerlingen, Germany, and Chapel Hill, N.C., USA August 9, 2012 -- Curetis AG and Cempra Inc. (NASDAQ:CEMP) today announced a research and development collaboration to incorporate Curetis' Unyvero pneumonia molecular diagnostic system into Cempra's upcoming global Phase 3 trial of the oral formulation of solithromycin, in patients with community-acquired bacterial pneumonia (CABP).
		Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results Date: August 8, 2012 Client: Cempra, Inc. Summary: CHAPEL HILL, N.C., Aug. 8, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the second quarter ended June 30, 2012. The company will host a conference call and webcast at 4:30 p.m. EDT, today.
		Next-Gen Drug Conjugates Attracting Funds, Partners Date: August 8, 2012 Client: Multiple Summary: The field of research surrounding antibody-drug conjugates (ADCs) and other peptide and small-molecule drug conjugates has heated up in the last 12 months following the approval of Seattle Genetics Inc.'s Adcetris (brentuximab vedotin), an ADC directed to CD30, to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large-cell lymphoma. It was the first ADC to gain approval. (See BioWorld Today, Aug. 6, 2012.)
		Puma Biotechnology to Present At Wedbush Pacgrow Life Sciences Conference Date: August 7, 2012 Client: Puma Biotechnology, Inc. Summary: LOS ANGELES, Calif., Aug. 7, 2012 - Puma Biotechnology, Inc. (OTCBB: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 12:45 p.m. EDT on Tuesday, August 14, at the Wedbush PacGrow 2012 Life Sciences Management Access Conference in New York.
		Domain-Backed Adynxx Enters the Wide Open World of Pain Drug R&D Date: August 7, 2012 Client: Adynxx Summary: You may not be able to tell by looking at the R&D pipelines of Big Pharma companies, but pain is one of the bigger opportunities in new drug development. There are cheap, decades-old drugs out there everyone knows about. There are not a whole lot of pain drugs in development based on really novel biological ideas. But that's a void that a San Francisco-based startup called Adynxx is seeking to fill.
		Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1 Date: August 7, 2012 Client: Adynxx Summary: SAN FRANCISCO, August 7, 2012 - Adynxx, a clinical stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today the completion of enrollment in the Phase 1 clinical study in healthy volunteers of its lead investigational drug candidate for the prevention of acute and chronic post-surgical pain, AYX1.
		Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases Date: August 6, 2012 Client: Cempra, Inc. Summary: CHAPEL HILL, N.C., Aug. 6, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the NIAID workshop Bridging the Gap -- Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases on August 9 to 10 in Rockville, MD. Dr. Fernandes will present how Cempra is working to overcome bottlenecks during the clinical development of one of its clinical candidates, solithromycin. The workshop is planned by the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, with the goal of helping to advance new therapeutics for infectious diseases through the product development pipeline.
		Milford Mirror (Conn.) Newspaper Article About 10-Year-Old Girl Who Benefited From Use Of IMRIS's Technology (intraoperative MRI) Date: August 5, 2012 Client: IMRIS Summary: Elena had surgery last year to remove a brain tumor, and today she's such an active community member that the school superintendent honored her for her achievements.
		New Published Data Demonstrate Endocyte's Targeted Small Molecule Drug Conjugate Approach Shows Promising Results in Polycystic Kidney Disease Model Date: August 3, 2012 Client: Endocyte, Inc. Summary: WEST LAFAYETTE, Ind., Aug 3, 2012 (GlobeNewswire via COMTEX) -- Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Endocyte's approach of utilizing a SMDC targeted to the folate receptor (FR) may provide a promising treatment for patients with autosomal-dominant polycystic kidney disease (ADPKD). In a mouse model of polycystic kidney disease (PKD), treatment with a folate-conjugated form of rapamycin, FC-rapa, (EC0371) strongly attenuated proliferation and growth of renal cysts and preserved renal function. The results were published online ahead of print in the Journal of the American Society of Nephrology and will be available in print in the October issue.
		Stemcells, Inc. Reports Second Quarter 2012 Financial Results and Provides Business Update Date: August 2, 2012 Client: StemCells, Inc. Summary: NEWARK, Calif., Aug 2, 2012 (GlobeNewswire via COMTEX) -- StemCells, Inc., a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the second quarter ended June 30, 2012 and provided a business update.
		ZIOPHARM Announces Second Quarter Financial Results and Key Developments Date: August 2, 2012 Client: Ziopharm Oncology, Inc. Summary: NEW YORK, Aug. 2, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today its financial results for the second quarter ended June 30, 2012, and provided an update on the Company's development activities.
		Endocyte Reports Second Quarter 2012 Financial Results and Business Update Date: August 2, 2012 Client: Endocyte, Inc. Summary: WEST LAFAYETTE, Ind., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced financial results for the second quarter ending June 30, 2012, and provided a business update.
		Endocyte Secures Doxil(R) Supply To Support Ongoing Phase 3 PROCEED Trial In Ovarian Cancer Date: August 2, 2012 Client: Endocyte, Inc. Summary: West Lafayette, Ind., Aug. 2, 2012 - Endocyte, Inc., (Nasdaq: ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company has secured DOXIL(R) (doxorubicin HCl liposome injection) supply from Janssen Products, LP, to supplement existing supply already in place to support the ongoing Phase 3 PROCEED trial in ovarian cancer. The PROCEED trial compares vintafolide in combination with DOXIL versus DOXIL alone for the treatment of folate-receptor positive platinum resistant ovarian cancer.
		ZIOPHARM Oncology Granted New U.S. Patent for Palifosfamide Date: August 2, 2012 Client: Ziopharm Oncology, Inc. Summary: NEW YORK, Aug. 2, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that the United States Patent and Trademark Office issued Patent No. 8,232,262 entitled "Salts of Isophosphoramide Mustard and Analogs Thereof as Anti-Tumor Agents" with claims directed to pharmaceutical compositions, methods of treatment and methods of making a novel DNA cross-linker, including palifosfamide (ZIO-201). This newly issued patent provides subject matter exclusivity through 2027. The patent estate covering palifosfamide compositions, formulations, methods of use and methods of manufacture now includes issued patents in the United States, Australia, Europe, New Zealand and South Africa, as well as pending applications in the United States and various foreign jurisdictions.
		Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9 Date: August 2, 2012 Client: Arena Pharmaceuticals Summary: SAN DIEGO, Aug. 2, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will report second quarter 2012 financial results after the NASDAQ Global Select Market closes on Thursday, August 9, 2012. The company will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) that day to discuss the results and provide a business and financial update.
		Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012 Date: August 1, 2012 Client: Cempra, Inc. Summary: CHAPEL HILL, N.C., Aug. 1, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that it will report second quarter 2012 financial results and provide a business update after the close of U.S. financial markets on August 8, 2012. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EDT, August 8, 2012.
		Independent Data Monitoring Committee of ZIOPHARM's Phase 3 Study of Palifosfamide in Metastatic Soft Tissue Sarcoma Recommends Continuation of Trial Following Planned Interim Futility Analysis Date: August 1, 2012 Client: Ziopharm Oncology, Inc. Summary: NEW YORK, Aug. 1, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today that the Independent Data Monitoring Committee of the Company's Phase 3 trial (PICASSO 3) of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has recommended continuation of the trial as designed and conducted. This is after completing a planned, pre-specified futility analysis using all available study data.